CN105026433A - VEGF与PDGFRβ双特异性融合蛋白及其用途 - Google Patents

VEGF与PDGFRβ双特异性融合蛋白及其用途 Download PDF

Info

Publication number
CN105026433A
CN105026433A CN201480010804.8A CN201480010804A CN105026433A CN 105026433 A CN105026433 A CN 105026433A CN 201480010804 A CN201480010804 A CN 201480010804A CN 105026433 A CN105026433 A CN 105026433A
Authority
CN
China
Prior art keywords
seq
pdgfr
fusion protein
bispecific fusion
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201480010804.8A
Other languages
English (en)
Other versions
CN105026433B (zh
Inventor
屈向东
曹国庆
叶鑫
陈侃
张蕾
许志宾
袁纪军
张连山
潘琴
管雁宾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN201480010804.8A priority Critical patent/CN105026433B/zh
Publication of CN105026433A publication Critical patent/CN105026433A/zh
Application granted granted Critical
Publication of CN105026433B publication Critical patent/CN105026433B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

提供的是VEGF与PDGFRβ双特异性融合蛋白及其用途。更具体地，提供了包含VEGFR胞外配体结合结构域和PDGFRβ抗体片段的双功能融合蛋白，可用于治疗湿性老年性黄斑变性(AMD)以及其它任何能够通过抑制VEGF和PDGF信号通路改善的疾病，比如肿瘤和糖尿病视网膜病变。

Description

PCT国内申请，说明书已公开。

Claims (43)

  1. PCT国内申请，权利要求书已公开。
CN201480010804.8A 2014-01-24 2014-12-11 VEGF与PDGFRβ双特异性融合蛋白及其用途 Active CN105026433B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201480010804.8A CN105026433B (zh) 2014-01-24 2014-12-11 VEGF与PDGFRβ双特异性融合蛋白及其用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2014100338215 2014-01-24
CN201410033821 2014-01-24
PCT/CN2014/093555 WO2015109898A1 (zh) 2014-01-24 2014-12-11 VEGF与PDGFRβ双特异性融合蛋白及其用途
CN201480010804.8A CN105026433B (zh) 2014-01-24 2014-12-11 VEGF与PDGFRβ双特异性融合蛋白及其用途

Publications (2)

Publication Number Publication Date
CN105026433A true CN105026433A (zh) 2015-11-04
CN105026433B CN105026433B (zh) 2018-10-19

Family

ID=53680783

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480010804.8A Active CN105026433B (zh) 2014-01-24 2014-12-11 VEGF与PDGFRβ双特异性融合蛋白及其用途

Country Status (3)

Country Link
CN (1) CN105026433B (zh)
TW (1) TW201609803A (zh)
WO (1) WO2015109898A1 (zh)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108757A (zh) * 2015-03-11 2017-08-29 新源生物科技股份有限公司 包含vegf及pdgf的配体结合域的融合蛋白
CN109021104A (zh) * 2017-06-12 2018-12-18 上海睿智化学研究有限公司 一种抗人血小板衍生生长因子β受体的抗体及其应用
CN111499762A (zh) * 2019-01-31 2020-08-07 四川大学华西医院 一种包含PDGFRβ特异性亲和体和TNFα的融合蛋白及其用途
CN113166249A (zh) * 2018-10-05 2021-07-23 首尔大学校产学协力团 Pdgf受体抗体及其用途
CN113164544A (zh) * 2018-10-12 2021-07-23 三钰生物科技股份有限公司 双功能性融合蛋白及其用途
WO2022018516A1 (en) * 2020-07-21 2022-01-27 Inspirar Limited Composition and method for treating eye diseases
CN114480492A (zh) * 2022-01-28 2022-05-13 景泽生物医药(合肥)有限公司 一种重组人抗体融合蛋白的制备方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN105111314B (zh) * 2015-08-13 2019-01-08 成都百世博生物技术有限公司 一种新型融合蛋白、药物组合物及其制备方法和用途
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
US11912754B2 (en) * 2017-10-12 2024-02-27 Immunowake Inc. VEGFR-antibody light chain fusion protein
CN111406071B (zh) * 2017-11-16 2024-01-16 成都硕德药业有限公司 Pas化的vegfr/pdgfr融合蛋白及其在治疗中的用途
AU2019227997A1 (en) * 2018-03-02 2020-09-24 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
CN111378044B (zh) * 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN113214406B (zh) * 2020-01-21 2022-08-02 苏州普乐康医药科技有限公司 一种结合gpc3融合蛋白的制备方法及应用
CN112225818B (zh) * 2020-10-16 2023-06-02 景泽生物医药(合肥)股份有限公司 去除/灭活病毒的方法
CN112210572B (zh) * 2020-10-16 2023-04-07 上海景泽生物技术有限公司 一种重组人抗体融合蛋白的制备方法
WO2022199603A1 (en) * 2021-03-25 2022-09-29 Nanjing GenScript Biotech Co., Ltd. Antibody fusion proteins and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113277A2 (en) * 2005-04-13 2006-10-26 Cell Genesys, Inc. Multivalent soluble tyrokinase receptor that bind angiogenic factor
CN101801407A (zh) * 2007-06-05 2010-08-11 耶鲁大学 受体酪氨酸激酶抑制剂及其使用方法
CN102219859A (zh) * 2011-05-20 2011-10-19 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
CN102250246A (zh) * 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
CN103002920A (zh) * 2010-04-30 2013-03-27 分子组合公司 抑制vegf-a受体相互作用的修饰结合蛋白
WO2013085972A1 (en) * 2011-12-05 2013-06-13 X-Body, Inc. Pdgf receptor beta binding polypeptides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113277A2 (en) * 2005-04-13 2006-10-26 Cell Genesys, Inc. Multivalent soluble tyrokinase receptor that bind angiogenic factor
CN101801407A (zh) * 2007-06-05 2010-08-11 耶鲁大学 受体酪氨酸激酶抑制剂及其使用方法
CN103002920A (zh) * 2010-04-30 2013-03-27 分子组合公司 抑制vegf-a受体相互作用的修饰结合蛋白
CN102219859A (zh) * 2011-05-20 2011-10-19 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
CN102250246A (zh) * 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
WO2013085972A1 (en) * 2011-12-05 2013-06-13 X-Body, Inc. Pdgf receptor beta binding polypeptides

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108757A (zh) * 2015-03-11 2017-08-29 新源生物科技股份有限公司 包含vegf及pdgf的配体结合域的融合蛋白
CN107108757B (zh) * 2015-03-11 2021-10-19 新源生物科技股份有限公司 包含vegf及pdgf的配体结合域的融合蛋白
CN109021104A (zh) * 2017-06-12 2018-12-18 上海睿智化学研究有限公司 一种抗人血小板衍生生长因子β受体的抗体及其应用
CN113166249A (zh) * 2018-10-05 2021-07-23 首尔大学校产学协力团 Pdgf受体抗体及其用途
CN113164544A (zh) * 2018-10-12 2021-07-23 三钰生物科技股份有限公司 双功能性融合蛋白及其用途
CN111499762A (zh) * 2019-01-31 2020-08-07 四川大学华西医院 一种包含PDGFRβ特异性亲和体和TNFα的融合蛋白及其用途
WO2022018516A1 (en) * 2020-07-21 2022-01-27 Inspirar Limited Composition and method for treating eye diseases
CN114480492A (zh) * 2022-01-28 2022-05-13 景泽生物医药(合肥)有限公司 一种重组人抗体融合蛋白的制备方法

Also Published As

Publication number Publication date
TW201609803A (zh) 2016-03-16
WO2015109898A1 (zh) 2015-07-30
CN105026433B (zh) 2018-10-19

Similar Documents

Publication Publication Date Title
CN105026433B (zh) VEGF与PDGFRβ双特异性融合蛋白及其用途
JP6140796B2 (ja) ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法
JP2022062120A (ja) ヒトＦｃＲｎ結合改変抗体及び使用方法
CN109988237A (zh) 检查点调节物拮抗剂
AU2017299581B2 (en) Humanized monoclonal antibodies that target ve-ptp (hptp-β)
JP6669882B2 (ja) 抗−ｃ−ＭＥＴ抗体及びその用途
US20210079081A1 (en) Long-acting and low-toxic recombinant anti-vegf humanized monoclonal antibody and production method therefor
JP2012521768A (ja) 抗体−受容体の組み合わせを含む多特異的結合性タンパク質を用いるための組成物および方法
CN107080843A (zh) 眼病的治疗
JP6328231B2 (ja) 抗ｖｅｇｆ抗体およびそれを含む癌または血管新生関連疾患を予防、診断、または治療するための医薬組成物
CN109311998A (zh) 用于增加免疫活性的ActRII拮抗剂
CN106459210A (zh) 用于治疗糖尿病黄斑性水肿的组合物和方法
JP2018515435A (ja) 組織透過性ペプチドと抗血管内皮細胞成長因子製剤が融合された融合タンパク質を有効成分として含む眼疾患の予防及び治療用薬学的組成物
KR20170077196A (ko) 향상된 il-6 항체
CN106604740A (zh) 用于治疗血管化癌症的改进的方法
JP6916776B2 (ja) Ａｎｇ−２に対する重鎖のみ抗体
CN104558175B (zh) 抗人vegf的重组嵌合抗体及其制备方法和用途
KR20220031666A (ko) 안과 질환의 맞춤 치료
JP5698534B2 (ja) 改良されたｎｏｇｏ−ａ結合分子およびその医薬的使用
CN105983093A (zh) 血管新生因子融合蛋白在制备用于治疗与血管新生相关的眼部疾病药物中的应用
WO2024114641A1 (en) C5/vegf bispecific binding molecules
RU2778023C1 (ru) Антитело к рецептору тромбоцитарного фактора роста (pdgf) и его применение

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant